These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3428323)

  • 1. Natural killer cell activity in patients with urologic cancer.
    Ma CP; Yu DS; Yeh MY; Chang SY; Han SH
    Eur Urol; 1987; 13(6):397-400. PubMed ID: 3428323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor.
    Mizutani Y; Yoshida O
    Int J Urol; 1994 Mar; 1(1):49-56. PubMed ID: 7627838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
    Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder.
    Carballido J; Alvarez-Mon M; Solovera OJ; Menéndez-Ondina L; Durántez A
    J Urol; 1990 Jan; 143(1):29-33. PubMed ID: 2294256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Moltó LM; Carballido J; Jurincic C; Lapeña P; Manzano L; Salmerón I; Klippel KF; Alvarez-Mon M
    Eur Urol; 1991; 19(1):74-8. PubMed ID: 2007423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
    Mizutani Y; Okada Y; Yoshida O; Bonavida B
    Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    J Urol; 1988 Oct; 140(4):890-4. PubMed ID: 3262173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
    Komatsu F; Kihara K
    Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder.
    Moltó LM; Carballido JA; Manzano L; Olivier C; Lapuerta M; Alvarez-Mon M
    Int J Immunopharmacol; 1993 Apr; 15(3):335-41. PubMed ID: 8505146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer.
    Mizutani Y; Nio Y; Fukumoto M; Yoshida O
    Cancer; 1992 Jan; 69(2):537-45. PubMed ID: 1728384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG; Zeuthen J; Claësson MH
    Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta enhances the natural killer activity of patients with bladder carcinoma.
    Moltó L; Carballido J; Manzano L; Olivier C; Lapeña P; Alvarez-Mon M
    Cancer Immunol Immunother; 1994 Jun; 38(6):406-10. PubMed ID: 8205562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
    Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
    Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cell activity of prostatic cancer patients.
    Choe BK; Frost P; Morrison MK; Rose NR
    Cancer Invest; 1987; 5(4):285-91. PubMed ID: 2444316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on human natural killer (NK) cell activity against cell lines derived from malignant urinary tract tumors. Part 1. Effects of human interferon-beta on augmentation of NK cell activity and its mechanism].
    Hayakawa M; Schmitz-Dräger BJ; Ackermann R
    Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):32-42. PubMed ID: 6737817
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effect of sera of breast cancer patients on NK cell activity].
    Konjević G; Spuzić I
    Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Killer activities of peripheral blood mononuclear cells in patients with bladder cancer].
    Okaneya T; Ogawa A
    Nihon Hinyokika Gakkai Zasshi; 1990 Apr; 81(4):532-7. PubMed ID: 2374325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Nio Y; Yoshida O
    J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.